Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2023.1148898
Abstract: Background Enzalutamide, as a second-generation endocrine therapy drug for prostate cancer (PCa), is prominent representative among the synthetic androgen receptor antagonists. Currently, there is lack of enzalutamide-induced signature (ENZ-sig) for predicting progression and relapse-free survival… read more here.
Keywords: progression; pca; enz sig; sig ... See more keywords